Amgen Inc. is experiencing a notable uptick in its stock price, driven by strategic partnerships and a robust pipeline.
Amgen Inc. (NASDAQ:AMGN) is rising today, gaining 2.17% to close at CA$394.00. This positive movement follows the announcement of a significant partnership with Veeva Systems, aimed at enhancing Amgen's commercial operations globally.
Investor takeaway: Investors should consider Amgen's strategic partnerships and pipeline developments as indicators of its potential for sustained growth in the competitive biopharma landscape.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$208.49B
P/E
24.0x
Div. yield
2.58%
Div. / share
$9.80
52W high
$447.03
52W low
$262.49
1W change
+2.20%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 21, 2026
Wall Street analysts forecast AMGN stock price to rise 1261.7% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$387.69
+1261.7% Upside
Previously C$388.03 on Sep 17, 2026
Current Price
C$28.47
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.3%
Annualized
90-Day Vol
33.0%
Annualized
Trend (90d)
+41.5%
Annualized drift
90d Mean
C$447.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$405.17 | C$355.06 – C$462.35 |
| 60 trading days | C$425.68 | C$353.18 – C$513.06 |
| 90 trading days | C$447.22 | C$355.80 – C$562.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's stock rises by 2.17% amid strategic partnership announcement.
The company's market cap stands at approximately $208.5 billion, reflecting its strong position in the biopharma sector.
Bull case
The recent partnership with Veeva Systems to deploy Vault CRM globally is expected to streamline Amgen's commercial operations. This could lead to increased efficiency and revenue growth. Additionally, Amgen's strong pipeline, especially in oncology, positions the company well for future success.
Bear case
Despite the positive news, Amgen faces challenges such as rising competition and price declines in some of its key products. The impending loss of exclusivity for certain drugs could also impact revenue streams.
Advertisement
Strategic Partnership with Veeva Systems
Amgen's recent decision to partner with Veeva Systems for a global rollout of its Vault CRM is a significant move aimed at modernizing its commercial operations. This partnership is expected to enhance the efficiency of Amgen's sales and marketing efforts, allowing for quicker deployment of new therapies worldwide. The collaboration underscores Amgen's commitment to leveraging advanced technology to improve patient engagement and operational effectiveness.
Strong Pipeline and Market Position
Amgen's diverse portfolio of drugs across oncology, cardiovascular, and immunology sectors continues to drive its growth. The company has several promising pipeline candidates, particularly in oncology, which are expected to bolster its market presence. Despite facing challenges from biosimilars and increased competition, Amgen's strategic initiatives and strong financial position suggest a positive outlook for the company.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
